Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

Wrexham have taken a significant step toward boosting their stadium’s capacity, having officially submitted a planning application to Wrexham City Borough Council. The club aims to add an extra 2,250 ...

The market expects Stoke Therapeutics, Inc. (STOK) to deliver a year-over-year decline in earnings on higher revenues when it ...

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

STOK has a tiny market cap of $629.50 million and a rather large “short interest” of more than 21%. Last quarter the company saw a nice beat on both earnings ($1.90) and revenues ($158 million ...

Here are some of the largest recent moves: FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327 MARSHALL WACE, LLP added 1,180,351 shares (+124.1% ...

Wrexham ’s Racecourse Ground will have a new name next season for the second time in its history following a lucrative sponsorship deal that is expected to earn the club a substantial seven ...

Wrexham's Racecourse Ground will be renamed the SToK Racecourse for next season in a deal that sees the world's oldest international stadium have a title sponsor for the first time. The stadium ...

The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by Jefferies on July 18, 2025. The analyst firm set a price target for $30.00 expecting STOK to rise to within 12 months ...

Stok Guru Tsechu is the main festival of Stok monastery. It is celebrated on the ninth and tenth day of the first month of Tibetan calendar. It comes one week prior to Matho Naranng festival of ...